Mantra Bio

Mantra Bio develops a novel next-generation, targeted therapeutics based on its proprietary platform for engineering Targeted Exosome Vehicles (TEVs). The Company's REVEAL platform, which integrates computational and wet biology, and automation, leverages the diversity of exosomes to enable the rational design of therapeutics directed at a wide range of tissue and cellular targets. Mantra Bio has also established a scalable biomanufacturing process and related technologies to ensure this new class of therapeutics is reproducibly made at high purity.

Mantra Bio headquartered in United States, North America, operates in the Biotechnology, Life Science sector. The company focuses on Biotechnology and has secured $816.0M in funding across 24 round(s). With a team of 11-50 employees, Mantra Bio is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Mantra Bio, raised $9.0M. Discover more about their projects, partnerships, and impact on our platform.